Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for lansoprazole (compound)

Name: lansoprazole
PubChem Compound ID: 3883
Molecular formula: C16H14F3N3O2S
Molecular weight: 369.363 g/mol
DivK1c_000920; KBioSS_002060; 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole; Ogast; Lanz; Spectrum_001580; D00355; Lanzopral; 1H-Benzimidazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-; AG 1749.
show more »
Name: lansoprazole
Name (isomeric): DB00448
Drug Type: small molecule
AG 1749
Brand: Opiren, Promp, Limpidex, Lanzol-30, Ogast, Lansoprazolum [INN-Latin], Agopton, Blason, Biuret Gr, Pro Ulco, Ogastro, Biuret Reagent, Lancid, Biuret, Aprazol, Prezal, Lansopep, Lanston, Takepron, Bamalite, Lanproton, Lanzopral, Lasoprol, Dakar, Zoprol, Ulpax, Lansoprazol [INN-Spanish], Prosogan, Mesactol, Zoton, Lanz, Prevpac, Amarin, Lanzor, Suprecid, Biuret Reagent Solution, Prevacid Iv, Ketian, Lansoprazole [Usan:Ban:Inn], Compraz, Prevacid Solutab, Monolitum, Ilsatec, Prevacid
Category: Anti-Infective Agents, Anti-Ulcer Agents, Enzyme Inhibitors, Proton-pump Inhibitors, Anti-Infectives
CAS number: 103577-45-3
Indication: For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
Lansoprazole, an acid proton-pump inhibitor similar to omeprazole, is used as an untiulcer drug in the treatment and maintenance of healing of duodenal or gastric ulcers, erosive and reflux esophagitis, NSAID-induced ulcer, Zollinger-Ellison syndrome, and Barrett's esophagus. Lansoprozole is active against Helicobacter pylori. The plasma eli...
show more »
Mechanism of Action:
Lansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but rather suppress gastric acid secretion by specific inhibition of the (H+,K+)-ATPase enzyme system at the secretory surface of the gastric...
show more »
Absorption: The absorption of lansoprazole is rapid, with mean Cmax occurring approximately 1.7 hours after oral dosing, and relatively complete with absolute bioavailability over 80%.
Protein binding: 97%
Biotransformation: Hepatic. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of lansoprazole). These metabolites have very little or no antisecretory activity. Lansoprazole is thought to be transformed into two active species which inhibit acid secretion by (H+,K+)-ATPase within the parietal cell canaliculus, but are not present in the systemic circulation.
Route of elimination: Following single-dose oral administration of PREVACID, virtually no unchanged lansoprazole was excreted in the urine. In one study, after a single oral dose of 14C-lansoprazole, approximately one-third of the administered radiation was excreted in the urine and two-thirds was recovered in the feces. This implies a significant biliary excretion of the lansoprazole metabolites.
Half Life: 1.5 (± 1.0) hours
Toxicity: Symptoms of overdose include abdominal pain, nausea and diarrhea.
Affected organisms: Humans and other mammals
Food interaction:
Avoid alcohol.
Food reduces bioavailabilty, but this has very little clinical impact.
Take 30-60 minutes before meals.
Drug interaction:
SucralfateSucralfate decreases the effect of lansoprazole
ClopidogrelLansoprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent lansoprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with lansoprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel.
IndinavirOmeprazole decreases the absorption of indinavir
AtazanavirThis gastric pH modifier decreases the levels/effects of atazanavir
EnoxacinLansoprazole may decrease the absorption of enoxacin.
show more »